monoclonal antibodies

Research into human diseases has led to the development of novel monoclonal antibody drugs. These monoclonal antibody therapies have been successful because of their specificity and selectivity. However, ongoing development and successfully launching a new mAb drug require robust and reliable methods to screen for drug targets, demonstrate drug safety and efficacy, and scale up manufacturing to meet the stringent regulatory guidelines required for approval.

Presented by: Katie Schaefer, PhD, Global Product Manager, Bio-Rad
Peter Winship, PhD, Technical Product Manager, Teledyne Cetac Technologies

View on demand

Purification is a multistep process toward confirmation of a target protein’s purity. In this webinar you will learn how to automate your protein purification workflow by following the creation of a hypothetical monoclonal antibody (mAb). Dr. Schaefer and Dr. Winship expertly demonstrate how the NGC Chromatography System and the AEX-500 series Autosampler work together to maximize screening capability as well as rapidly achieve therapeutic development objectives.

As phase 3 clinical trials of investigational vaccines for COVID-19 begin in the U.S., you may be wondering what it takes to make an effective vaccine? In case you missed it, check out our Hanging with My Chromies podcast, episodes 6 and 10 on vaccine development and viral spread, and learn about the role chromatography plays in making a successful vaccine.

Biologics are transforming the healthcare landscape and bringing us closer to the realization of personalized solutions to our health problems. Learn about what biologics are and how protein purification plays a key role in their overall success as a therapeutic.

Use our interactive infographic to find out how your resin-of-choice fares in on-column aggregate formation during monoclonal antibody purification. And find out what you can do to minimize these on-column aggregates.